Heart Failure Treatment Articles & Analysis
10 articles found
Any disruption in this system can lead to conditions such as hypertension, atherosclerosis, and heart failure. Research in cardiovascular biology aims to unravel the underlying causes of these diseases and improve therapeutic interventions. ...
Heart failure with preserved ejection fraction (HFpEF) has recently been recognized as the single greatest unmet need in cardiovascular medicine, overtaking heart failure with reduced ejection fraction (HFrEF) and becoming the most common form of heart failure, with a prevalence that is ...
Heart failure with preserved ejection fraction (HFpEF) is currently affecting over half of heart failure patients. ...
Diastolic heart failure has many of the same symptoms as other types of heart failure. ...
Recent clinical trials investigating sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions ...
This 81 year-old Lady was implanted two weeks before the measurement with a bi-ventricular pacemaker to treat her heart failure with resynchronization therapy. Different stimulation modes have been tested and their outcome in terms of stroke volume has been assessed. The stoke volume was much better in left ventricular stimulation only (LV) compared to right ventricular stimulation only (RV). ...
The first clinical data of an implantable heart sensor with remote measurement capacity was presented at the prestigious ESC Heart Failure 2022 Late-Breaking Science event Israel-based Vectorious Medical Technologies announced the positive results from the VECTOR-HF I study of its V-LAP novel wireless system. ...
The V-LAP system is the first digital, wireless, battery-free device that can communicate from deep within the body using high-resolution waveform morphology, according to the Tel Aviv-based startup. Because the pressure of the heart’s left atrium is the earliest and most accurate real-time indication of heart failure exacerbation, company ...
Ancora Heart Inc., a Santa Clara, Calif.-based company looking to help those with heart failure, is heralding results from an interim analysis of patients treated in a U.S. early feasibility study evaluating the safety of the investigational Accucinch ventricular repair system. The multicenter, nonrandomized, prospective study is assessing the system in patients with symptomatic heart failure ...
–September 25, 2019–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an interim analysis of heart failure patients treated in the CorCinch FMR study, a U.S. early feasibility study evaluating the safety of the investigational ...